Objective: To investigate prognosis and prognostic factors in patients with hypertrophic cardiomyopathy (HCM) in Japan.
Design: A nationwide epidemiological study.
Setting: Hospitals selected randomly from among all hospitals in Japan.
Patients: Clinical and epidemiological information for 2155 patients with HCM were collected in 1999.
Main outcome measures: Patients were classified on the basis of baseline prognostic factors. Survival rates up to 5 years were calculated by Cox’s proportional hazard model for 1605 patients.
Results: During the follow-up period, 241 deaths were recorded. The crude 5-year survival rate for the entire cohort was 86% (95% CI 84 to 88), and annual mortality ranged from 2.2% to 3.0%. A higher cardiothoracic ratio on chest x ray (HR 1.61; 95% CI 1.26 to 2.05, with 1 SD (6.2%) increase), a lower left ventricular ejection fraction (HR 1.42; 95% CI 1.20 to 1.69, with 1 SD (13%) decrease) and the presence of left bundle branch block (HR 3.14; 95% CI 1.28 to 7.71) were independently associated with a poorer prognosis, whereas the presence of apical hypertrophy at baseline (HR 0.58; 95%CI 0.36 to 0.92) predicted a better chance of survival.
Conclusions: The nationwide survey of patients with hypertrophic cardiomyopathy yielded important information on its prognosis and prognostic factors. These observations afford, for the first time, a measure of risk stratification in patients with HCM in Japan.
- AF, atrial fibrillation
- BMI, body mass index
- HCM, hypertrophic cardiomyopathy
- IVS, interventricular septum
- LBBB, left bundle branch block
- LVEF, left ventricular ejection fraction
- LV, left ventricular
- NYHA, New York Heart Association
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Published Online First 3 November 2006
Competing interests: None declared.
We disclose that there are no other financial, personal or professional relationships with other people or organisations that could be perceived as conflicts of interest, or as potentially influencing or biasing this work.